BMO Capital Maintains Outperform Rating for Structure Therapeutics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
BMO Capital has maintained its Outperform rating for Structure Therapeutics (NASDAQ:GPCR) and increased its price target from $40.00 to $83.00. Structure Therapeutics is a clinical-stage global biopharmaceutical company developing novel oral therapeutics for chronic diseases. Its shares are currently trading up 2.28% at $57.89 per share.
October 03, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital has maintained its Outperform rating for Structure Therapeutics and raised its price target, indicating a positive outlook for the company's stock.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. BMO Capital's decision to maintain an Outperform rating and raise the price target for Structure Therapeutics suggests a positive outlook for the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100